GlassScriptPhysician profile
Sarah Pederson
NPI 1407313968
$2,510.96
in general payments reported to CMS, 2019-2025
24 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $113 · 2023: $866 · 2024: $1,132 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.03 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $406.77 | 2022-2025 | |
| Amgen INC. | $301.14 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $265.37 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $256.31 | 2023-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $248.46 | 2023-2024 | Xarelto |
| Pfizer INC. | $147.67 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.09 | 2023-2025 | Jardiance |
| Boston Scientific Corporation | $112.89 | 2023-2025 | Watchman Flx, Varithena Administration Pack, Watchman |
| Irhythm Technologies, INC. | $70.19 | 2024 | Zio Monitor, Zio Xt Patch, Zio At Patch |
| Astrazeneca Pharmaceuticals LP | $64.40 | 2024 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $57.81 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $57.39 | 2023-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $47.81 | 2023-2024 | |
| Abiomed | $47.35 | 2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $46.18 | 2022-2023 | Uptravi, Opsumit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.05 | 2024-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $40.29 | 2023-2024 | Linq II, Micra |
| Tactile Systems Technology INC | $37.41 | 2023-2024 | Flexitouch Plus, Entre Plus |
| Kci USA, INC. | $32.48 | 2022 | |
| Bard Peripheral Vascular, INC. | $28.97 | 2023-2025 | Venovo |
| Alnylam Pharmaceuticals INC. | $27.19 | 2023 | Amvuttra |
| Solventum Corporation | $25.12 | 2025 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Kiniksa Pharmaceuticals, LTD. | $17.55 | 2023 | Arcalyst |
| Pacira Pharmaceuticals Incorporated | $13.07 | 2024 | Zilretta, Exparel, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Pederson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.